Drug Abuse Treatment Market, By Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction), By Drug Type (Disulfiram, Acamprosate, Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In : Dec 2023

Code : CMI2011

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Drug Abuse Treatment MarketSize and Trends

Global drug abuse treatment market is expected to reach US$ 20.70 Bn by 2030, from US$ 35.74 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period.

Novel drug development: The development of novel drug treatments is playing a vital role in driving the growth of the global drug abuse treatment market. Pharmaceutical companies are actively researching and developing advanced medications that can more effectively treat substance abuse disorders and help patients in greater number to recover. Some of the novel drugs in pipeline aim to minimize withdrawal symptoms, reduce drug cravings, block drug rewarding effects and modify brain circuits involved in addiction.
Focus on newer therapies like cannabidiol and psychedelic drugs: Cannabidiol, which is derived from cannabis plants has shown early promise for treating substance abuse disorders and managing withdrawal symptoms from drugs like opioids, cocaine and alcohol. Studies by World Health Organization (WHO) and National Institute of Health (NIH) have found Cannabidiol (CBD) effective in reducing cravings and relapse rates when used in conjunction with other therapies. The non-intoxicating nature of CBD makes it more acceptable to patients and doctors than conventional medical cannabis treatment. With overdose deaths reaching catastrophic levels, CBD offers a relatively safe approach and presents the possibility of an affordable therapy. As more clinical trials report success, CBD is likely to gain mainstream acceptance and drive significant gains for drug abuse treatment programs focused on this approach.
Increasing adoption of generic drugs for addiction treatment: Rising availability and usage of generic medications for addiction treatment is significantly impacting the drug abuse treatment market on a global scale. More affordable generic alternatives to branded opioid addiction medications like buprenorphine and methadone are becoming increasingly widespread. This shift with the opioid overdose crisis in many nations worsens the demand for low-cost evidence-based treatment options. For instance, in September 2021, Endo International plc. a pharmaceutical company launched generic version of Pfizer's Chantix (varenicline), 0.5 mg and 1 mg tablets after getting approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
Increasing adoption of personalized treatment programs: Traditional "one-size-fits-all" treatment programs that focused solely on medication or counseling are being replaced by more tailored and holistic approaches. This recognizes that no two patients are the same and effective treatment must be customized, based on each individual's circumstances, including the specific drugs abused, co-occurring conditions like mental illness, and socioeconomic factors. Personalized treatment plans may incorporate a mix of medication, counseling or therapy targeted to a person's needs, preferences, and lifestyle.